Christie Hospital NHS Trust"Wilmslow RoadManchester M20 4BXUKTel 44-(0)161-446-3136Fax 44-(0)161-446-3136

www.paterson.man.ac.uk

Statement on Dr Anesa Ahamad

The Masters of Science in Oncology Programme

The MSc. in Oncology was originally designed for Junior Doctors who werespecialising in Medical Oncology and to serve as a common core curriculum foradvanced medical training. This was the first MSc course of its type establishedin the UK. Since establishment, the course has changed so that both Medical andClinical Oncologists benefit from the compulsory and advanced modules, four ofwhich allow simultaneous study for Royal College of Radiologists Fellowshipexaminations (recognised by the College as UK training). Its major aim is todeliver, an iacadernic ,and clinical, understanding, of modern oncology. Theresearchcomponent.ofthe courseallowsstudentsto receive practical training inplanning"implementipg and.interpretinq. cf piece ',of research and. together theseform a specialised postgraduate degree that helps in attaining the :hlghestprofessional advancement in Oncology.

The Prize

Dr Ahamad will graduate with a Master of Science in Oncology from theUniversity of Manchester in 2003. Her degree consisted of 8 lecture modulescovering all aspects of current cancer research and treatment that are examinedby dissertation or written examination. It is taught by established experts from theUniversity of Manchester, the Paterson Institute for Cancer Research and invitedspecialist lecturers from the UK and Europe. One third of her degree consisted ofa clinical based research project that has been examined by thesis. Dr Ahamadwas awarded a discretionary prize in 2000 by the Christie Hospital MedicalEducation Committee in recognition of her outstanding performance in the MScexaminations of that year. She is one of only 2 students (out of 35 students) tohave been awarded this prize since the course started in 1995.

The University"

The University of Manchester is' the oldest civic University in the UK and has oneof the largest Faculties of Medicine.Dentistry,' Nursing and Pharmacy in Europeknown for over 200 years for Its innovative teaching and extensive research,Although centred around the University, teaching and research is spread over awide area within a 50 mile radius of Manchester with links to Manchester RoyalInfirmary, St Mary's, Hope, Withington, Christie Hospital, North Manchester

~-'IGeneral, Stepping Hill and Tameside General Hospitals, Booth Hall and RoyalManchester Children's Hospitals and local Community NHS Trusts. An innovatorin curricular development; it was the first UK Faculty to adopt fully problem-basedlearning in Medicine and Dentistry. In the 2000 independent review of its teachingincluding the postgraduate programmes, the Medical School attained maximumscores in all areas. The Faculty has 1,500 staff and an annual budget of £30million. Its student population comprises over 3,500 candidates registered forundergraduate degree (including intercalated-year degree) and diplomaprogrammes and 1000 postgraduates on award-bearing courses. Its annualresearch income of £17 million is approximately one third of the total for theUniversity of Manchester. For graduate students, the Faculty forms part of theUniversity's Graduate School in Science, Engineering and Medicine, but retains ahigh degree of autonomy.

The Christie Hospital

The Christie Hospital NHS Trust is the largest cancer treatment centre of its kind inEurope, and an international leader in cancer research and development. TheChristie covers a population of 3.5 million and treatments include radiotherapy,chemotherapy, surgery, transplants and endocrinology. Every year approximately11,000 new patients registered; 15,000 in-patient stays; 14,500 day-case stays;and 139,500 outpatient attendances. Approximately 1,700 staff work on the Trustsite, plus over 200 volunteers. The Hospital was first opened as the CancerPavilion and Home for Incurables in 1892. Nine years later, in November 1901, itwas named The Christie Hospital. World firsts for the Christie include; thepioneering the use of Roentgen X-rays for cancer therapy (1901); setting the firstinternational standards for radiation treatment (1932); conducting the world s firstever clinical trial for a new breast cancer drug (1944); first clinical trials for breastcancer drug Tamoxifen (1970); pioneering work into the use of cultured bonemarrow for leukaemia treatment (1986); shaping radio therapy beam to matchtumour mass (1990), pioneering the use of stem cells from a single blood sampleto protect bone marrow from the effects of treatment (1991); inventing photo-dynamic therapy for skin cancr!J19~~_~<=!.~!;~~~,~~~i~.~",~()r cervical cancer (2000

~ PfJ'lt~0-~';!~~'~~":~::"~_~'~'i:r',~__..~ , ~::~.::~:::':....::~~~p/~!'~r::;~~';:;L~{;:·;;:. il.:. i\;;U:-: .,'I /t V);:.M /OW R0.. /

'A/l f ,:rnUr~gT'\~;

L·'.'t( ..;;'L;,:::l

"~",~:~2,:;".::~,,'"Dr Graham Cowling has been the Programme Director of the Master of Science inOncology Degree Course since 1997 and as Postgraduate Tutor for CancerStudies is in charge of all Oncology postgraduate taught and research degreecourses including MPhil, MD and PhD in the University of Manchester.

Dr Graham Cowling9th January 2003

TII[ lINl\'rltSITl

~1·\t,\~Cll[STI1i www.paterson.man.ac.UI\/ education/